MTIP

Managing Partner Dr. Christoph Kausch leads the investment team from the firm's Basel headquarters. The senior leadership group includes Partner and CFO Christoph Vonder Mühll, who oversees financial operations, and Investment Partner Katrin Vatiska. Board-level oversight is provided by Chairman Benjamin Gilgen and board member Daniela Nienstedt.

MTIP sources proprietary deal flow through its sector-specialist network, targeting European healthcare technology companies that are post-revenue with strong growth trajectories. It structures both majority and minority investments directly, preferring active board engagement and long-term value-creation plans over passive positions. The firm does not operate a fund-of-funds model and does not syndicate its origination widely to generalist co-investors.

The firm targets growth, expansion stage, and late-stage buyout transactions. It avoids early-stage venture or pre-revenue biotech assets. The strategy aims for companies with proven commercial traction in regulated healthcare markets, typically those with established software or AI-enabled platforms that can scale across multiple European countries.

MTIP is exclusively a healthcare technology investor — the entire firm is structured around this single vertical. In contrast to generalist firms where healthcare is one of many allocations, MTIP's investment professionals, deal sourcing, due diligence, and portfolio management operate within a single specialist mandate. This narrow focus shapes its origination network, its ability to assess technical and regulatory risk, and its portfolio governance approach.

Yes. MTIP classifies its Fund II as Article 9 under the EU's Sustainable Finance Disclosure Regulation (SFDR), signifying a sustainable investment objective. It uses a proprietary Impact Tracker built on the AAAQ framework — Availability, Accessibility, Acceptability, and Quality — to measure how its portfolio companies improve healthcare access. The firm is also a Certified B Corporation and a PRI signatory.

MTIP focuses on AI-enabled and software-driven companies that form the digital infrastructure of healthcare. This includes clinical workflow automation, surgical intelligence, pharmaceutical supply-chain compliance and R&D analytics, digital therapeutics for chronic disease management, radiology platform technology, and connected medical devices. It does not invest in traditional biotech or early-stage pharmaceutical discovery.

The firm invests across the European continent, with confirmed activities in 12 European countries. Its portfolio includes companies headquartered in Switzerland, Germany, the United Kingdom, Spain, and the Nordics, among other regions. MTIP does not publicly indicate any investment activity outside of Europe.